UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2019-01, Vol.20 (1), p.88-99

2019

Volltextzugriff (PDF)

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy

JNCI : Journal of the National Cancer Institute, 2017-01, Vol.109 (4), p.djw259

2017

Volltextzugriff (PDF)

Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer

Journal of surgical oncology, 2013-09, Vol.108 (4), p.236-241

2013

Volltextzugriff (PDF)

Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer

JNCI : Journal of the National Cancer Institute, 2023-11, Vol.115 (11), p.1302-1309

2023

Volltextzugriff (PDF)

Oral Uracil and Tegafur Plus Leucovorin Compared With Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-06

Journal of clinical oncology, 2006-05, Vol.24 (13), p.2059-2064

2006

Volltextzugriff (PDF)

Randomized psychosocial interventions for breast cancer: impact on life purpose

Psycho-oncology (Chichester, England), 2016-06, Vol.25 (6), p.618-625

2016

Volltextzugriff (PDF)

Immunohistochemical Surrogate Markers of Breast Cancer Molecular Classes Predicts Response to Neoadjuvant Chemotherapy: A Single Institutional Experience With 359 Cases

Cancer, 2010-03, Vol.116 (6), p.1431-1439

2010

Volltextzugriff (PDF)

21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology

Breast cancer research and treatment, 2018-02, Vol.168 (1), p.69-77

2018

Volltextzugriff (PDF)

Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28

Journal of clinical oncology, 2005-06, Vol.23 (16), p.3686-3696

2005

Volltextzugriff (PDF)

Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer

Journal of clinical oncology, 2002-09, Vol.20 (17), p.3605-3616

2002

Volltextzugriff (PDF)

Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors

Modern pathology, 2017-08, Vol.30 (8), p.1078-1085

2017

Volltextzugriff (PDF)

Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Journal of clinical oncology, 2008-06, Vol.26 (16), p.2644-2652

2008

Volltextzugriff (PDF)

Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38

Cancer epidemiology, biomarkers & prevention, 2016-01, Vol.25 (1), p.51-59

2016

Volltextzugriff (PDF)

Phase II Study of Induction Fixed-Dose Rate Gemcitabine and Bevacizumab Followed by 30 Gy Radiotherapy as Preoperative Treatment for Potentially Resectable Pancreatic Adenocarcinoma

Annals of surgical oncology, 2013-11, Vol.20 (12), p.3787-3793

2013

Volltextzugriff (PDF)

HER2 targeting in early breast cancer: more options and more questions

Oncology (Williston Park, N.Y.), 2014-04, Vol.28 (4), p.293-294

2014

Volltextzugriff (PDF)

Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial

Bone (New York, N.Y.), 2016-09, Vol.90, p.123-126

2016

Volltextzugriff (PDF)

Quality of Life in Operable Colon Cancer Patients Receiving Oral Compared With Intravenous Chemotherapy: Results From National Surgical Adjuvant Breast and Bowel Project Trial C-06

Journal of clinical oncology, 2007-02, Vol.25 (4), p.424-430

2007

Volltextzugriff (PDF)

Single‐fraction radiosurgery for the treatment of spinal breast metastases

Cancer, 2005-11, Vol.104 (10), p.2244-2254

2005

Volltextzugriff (PDF)

Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer

Modern pathology, 2011-03, Vol.24 (3), p.367-374

2011

Volltextzugriff (PDF)

Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory study

SpringerPlus, 2016-04, Vol.5 (1), p.422-422, Article 422

2016

Volltextzugriff (PDF)

Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer

Annals of surgical oncology, 2011-04, Vol.18 (4), p.1122-1129

2011

Volltextzugriff (PDF)

Breast cancer: never too young for a functional assessment?

Oncology (Williston Park, N.Y.), 2012-09, Vol.26 (9), p.811-812

2012

Volltextzugriff (PDF)

Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer

Annals of surgical oncology, 2011-12, Vol.18 (Suppl 3), p.323-323

2011

Volltextzugriff (PDF)

Metabolic effects of hormone deprivation therapy: weighing the evidence

Oncology (Williston Park, N.Y.), 2010-08, Vol.24 (9), p.846-847

2010

Volltextzugriff (PDF)

1 – 25 von 86

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(85)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(55)
Female
(51)
Science & Technology
(51)
Life Sciences & Biomedicine
(50)
Middle Aged
(44)
Oncology
(40)
Adult
(32)
Aged
(31)
Breast Neoplasms - Drug Therapy
(25)
Male
(24)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(20)
Treatment Outcome
(17)
Disease-Free Survival
(16)
Chemotherapy
(13)
Breast Cancer
(12)
Breast Neoplasms - Pathology
(12)
Fluorouracil - Administration & Dosage
(12)
Neoplasm Staging
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial

Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer

Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer

Oral Uracil and Tegafur Plus Leucovorin Compared With Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-06

Randomized psychosocial interventions for breast cancer: impact on life purpose

Immunohistochemical Surrogate Markers of Breast Cancer Molecular Classes Predicts Response to Neoadjuvant Chemotherapy: A Single Institutional Experience With 359 Cases

21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology

Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28

Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer

Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors

Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38

Phase II Study of Induction Fixed-Dose Rate Gemcitabine and Bevacizumab Followed by 30 Gy Radiotherapy as Preoperative Treatment for Potentially Resectable Pancreatic Adenocarcinoma

HER2 targeting in early breast cancer: more options and more questions

Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial

Quality of Life in Operable Colon Cancer Patients Receiving Oral Compared With Intravenous Chemotherapy: Results From National Surgical Adjuvant Breast and Bowel Project Trial C-06

Single‐fraction radiosurgery for the treatment of spinal breast metastases

Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer

Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory study

Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer

Breast cancer: never too young for a functional assessment?

Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer

Metabolic effects of hormone deprivation therapy: weighing the evidence

Suchergebnisse filtern